Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Next Previous
X
Search
Trial Profile

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NTLA-2001 (Primary)
  • Indications Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MAGNITUDE
  • Sponsors Intellia Therapeutics

    • Most Recent Events

    • 18 Mar 2024 According to an Intellia Therapeutics media release, Julian Gillmore, M.D., Ph.D., Professor of Medicine, National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, U.K., is the national coordinating investigator of the Phase 3 study.
    • 18 Mar 2024 According to an Intellia Therapeutics media release, first patient has been dosed in this trial. With multiple sites now enrolling patients, including in the U.S.
    • 04 Jan 2024 According to an Intellia Therapeutics media release, the company anticipates to dose the first patient in MAGNITUDE trial of NTLA-2001 for the treatment of ATTR-CM in Q1 2024, and continue to open new sites and enroll patients, globally, in the MAGNITUDE study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top